CN116966234A - Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof - Google Patents
Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof Download PDFInfo
- Publication number
- CN116966234A CN116966234A CN202310904798.1A CN202310904798A CN116966234A CN 116966234 A CN116966234 A CN 116966234A CN 202310904798 A CN202310904798 A CN 202310904798A CN 116966234 A CN116966234 A CN 116966234A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- medicine
- diabetic retinopathy
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 77
- 206010012689 Diabetic retinopathy Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 46
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 46
- 241000405414 Rehmannia Species 0.000 claims abstract description 31
- 235000006533 astragalus Nutrition 0.000 claims abstract description 27
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 24
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 24
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 24
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 24
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 21
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 21
- 241000545744 Hirudinea Species 0.000 claims abstract description 21
- 241001061264 Astragalus Species 0.000 claims abstract description 20
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 20
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 20
- 210000004233 talus Anatomy 0.000 claims abstract description 20
- 235000003956 Luffa Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 19
- 238000009835 boiling Methods 0.000 claims description 18
- 241000219138 Luffa Species 0.000 claims description 17
- 241001295925 Gegenes Species 0.000 claims description 13
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 8
- 241000045403 Astragalus propinquus Species 0.000 claims description 7
- 244000280244 Luffa acutangula Species 0.000 claims description 6
- 235000009814 Luffa aegyptiaca Nutrition 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 229940107666 astragalus root Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 244000050983 Luffa operculata Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 244000241838 Lycium barbarum Species 0.000 description 5
- 235000015459 Lycium barbarum Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 241000220485 Fabaceae Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004377 improving vision Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038862 Retinal exudates Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a traditional Chinese medicine for treating diabetic retinopathy and a preparation method thereof, wherein the traditional Chinese medicine comprises the following components in parts by weight: 1-840 parts of American ginseng, 1-840 parts of astragalus, 1-280 parts of safflower, 1-119 parts of pearl, 1-840 parts of radix puerariae, 1-140 parts of leech, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica, 1-609 parts of cassia seed, 1-609 parts of luffa and 1-140 parts of cassia twig. The preparation process is simple, the treatment is convenient, and the curative effect is exact.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating diabetic retinopathy and a preparation method thereof.
Background
Diabetes is a metabolic disease characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological action, or both. Long-standing hyperglycemia leads to chronic damage, dysfunction, of various tissues, especially the eyes, kidneys, heart, blood vessels, nerves. Diabetic Retinopathy (DR) is one of the most common microvascular complications of diabetes, being retinal microvascular leakage and blockage caused by chronic progressive diabetes, resulting in a range of fundus pathologies such as microangioma, hard exudation, cotton-wool spots, neovascularization, vitreous proliferation, macular edema, and even retinal detachment. DR is classified into proliferative diabetic retinopathy and nonproliferative diabetic retinopathy, with the presence or absence of abnormal neovascularization emanating from the retina as a criterion.
The prior patent of application number 200410092407.8 discloses a traditional Chinese medicine for treating diabetic retinopathy, which is prepared from the following raw materials in parts by weight: the traditional Chinese medicines comprise 10-30 parts of astragalus membranaceus, 10-20 parts of ophiopogon root, 10-30 parts of radix puerariae, 10-30 parts of wolfberry fruit and 10-30 parts of radix salviae miltiorrhizae, and although the traditional Chinese medicines can treat diabetic retinopathy to a certain extent, the effect of preventing the occurrence of the diabetic retinopathy or slowing down the progress of the diabetic retinopathy still needs to be further improved. Therefore, there is a need to propose a traditional Chinese medicine for treating diabetic retinopathy and a preparation method thereof, so as to solve the above problems.
Disclosure of Invention
The application aims at overcoming the defects of the prior art, and provides a traditional Chinese medicine for treating diabetic retinopathy and a preparation method thereof, so as to solve the problem that the effect of the traditional Chinese medicine for treating diabetic retinopathy on preventing the occurrence or slowing down the progress of the diabetic retinopathy is still to be further improved.
In a first aspect, the application provides a traditional Chinese medicine for treating diabetic retinopathy, which comprises the following components in parts by weight: 1-840 parts of American ginseng, 1-840 parts of astragalus, 1-280 parts of safflower, 1-119 parts of pearl, 1-840 parts of radix puerariae, 1-140 parts of leech, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica, 1-609 parts of cassia seed, 1-609 parts of luffa and 1-140 parts of cassia twig.
Further, the composition comprises the following components in parts by weight: 1-840g of American ginseng, 1-840g of astragalus, 1-280g of safflower, 1-119g of pearl, 1-840g of radix puerariae, 1-140g of leech, 1-840g of medlar, 1-609g of rehmannia, 1-609g of angelica, 1-609g of cassia seed, 1-609g of luffa and 1-140g of cassia twig.
Further, the composition comprises the following components in parts by weight: 400g of American ginseng, 400g of astragalus, 140g of safflower, 60g of pearl, chai Gegen g of leech, 70g of medlar, 420g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of loofah sponge and 70g of cassia twig.
Further, the composition comprises the following components in parts by weight: 840g of American ginseng, 840g of astragalus, 280g of safflower, 119g of pearl, chai Gegen g of leech, 140g of medlar 840g, 609g of rehmannia, 609g of angelica, 609g of cassia seed, 609g of loofah sponge and 140g of cassia twig.
In a second aspect, the application provides a method for preparing a traditional Chinese medicine for treating diabetic retinopathy, comprising the following steps:
step one, providing the following components in parts by weight: 1-840 parts of astragalus membranaceus, 1-840 parts of radix puerariae, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica sinensis, 1-609 parts of semen cassiae, 1-609 parts of luffa and 1-140 parts of cassia twig; mixing and grinding the components;
step two, heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues;
step three, heating, boiling and decocting the first medicine residues and 70% ethanol for 2 hours, and filtering to obtain second medicine liquid and second medicine residues;
step four, heating, boiling and decocting the second medicine residues and 70% ethanol for 2 hours, and filtering to obtain third medicine liquid and third medicine residues;
fifthly, mixing and filtering the first liquid medicine, the second liquid medicine and the third liquid medicine to obtain extractum;
step six, mixing and drying 1-840 parts of American ginseng, 1-119 parts of pearl and 1-140 parts of leech into powder and extractum to prepare the premixed raw material.
And seventhly, mixing and drying 1-280 parts of safflower and the premixed raw materials to prepare the traditional Chinese medicine for treating diabetic retinopathy.
Further, in the first step, the following components by weight are provided: 1-840g of astragalus root, 1-840g of radix puerariae, 1-840g of medlar, 1-609g of rehmannia, 1-609g of angelica, 1-609g of cassia seed, 1-609g of luffa and 1-140g of cassia twig.
Further, in the first step, the following components by weight are provided: 400g of astragalus, chai Gegen g of medlar 420g, 300g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of luffa, and 70g of cassia twig.
Further, in the first step, the following components by weight are provided: radix astragali 840g, chai Gegen g, fructus Lycii 840g, rehmanniae radix 609g, radix Angelicae sinensis 609g, semen Cassiae 609g, retinervus Luffae fructus 609g, ramulus Cinnamomi 140g.
The application has the following beneficial effects: the application provides a traditional Chinese medicine for treating diabetic retinopathy and a preparation method thereof, wherein the traditional Chinese medicine comprises the following components in parts by weight: 1-840 parts of American ginseng, 1-840 parts of astragalus, 1-280 parts of safflower, 1-119 parts of pearl, 1-840 parts of radix puerariae, 1-140 parts of leech, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica, 1-609 parts of cassia seed, 1-609 parts of luffa and 1-140 parts of cassia twig. The application has simple preparation process, convenient treatment and no toxic or side effect.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a flow chart of a preparation method of the traditional Chinese medicine for treating diabetic retinopathy.
Detailed Description
It should be noted that, without conflict, the embodiments of the present application and features of the embodiments may be combined with each other. The application will be described in detail below with reference to the drawings in connection with embodiments. It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
Spatially relative terms, such as "above … …," "above … …," "upper surface at … …," "above," and the like, may be used herein for ease of description to describe one device or feature's spatial location relative to another device or feature as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as "above" or "over" other devices or structures would then be oriented "below" or "beneath" the other devices or structures. Thus, the exemplary term "above … …" may include both orientations of "above … …" and "below … …". The device may also be positioned in other different ways (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
Exemplary embodiments according to the present application will now be described in more detail with reference to the accompanying drawings. These exemplary embodiments may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. It should be appreciated that these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the concept of these exemplary embodiments to those skilled in the art, that in the drawings, thicknesses of layers and regions are exaggerated for clarity, and identical reference numerals are used to denote identical devices, and thus descriptions thereof will be omitted.
The embodiment of the application provides a traditional Chinese medicine for treating diabetic retinopathy, which comprises the following components in parts by weight:
1-840 parts of American ginseng, 1-840 parts of astragalus, 1-280 parts of safflower, 1-119 parts of pearl, 1-840 parts of radix puerariae, 1-140 parts of leech, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica, 1-609 parts of cassia seed, 1-609 parts of luffa and 1-140 parts of cassia twig.
Specifically, the composition comprises the following components in parts by weight: 1-840g of American ginseng, 1-840g of astragalus, 1-280g of safflower, 1-119g of pearl, 1-840g of radix puerariae, 1-140g of leech, 1-840g of medlar, 1-609g of rehmannia, 1-609g of angelica, 1-609g of cassia seed, 1-609g of luffa and 1-140g of cassia twig.
Preferably, the composition comprises the following components in parts by weight: 400g of American ginseng, 400g of astragalus, 140g of safflower, 60g of pearl, chai Gegen g of leech, 70g of medlar, 420g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of loofah sponge and 70g of cassia twig.
Preferably, the composition comprises the following components in parts by weight: 840g of American ginseng, 840g of astragalus, 280g of safflower, 119g of pearl, chai Gegen g of leech, 140g of medlar 840g, 609g of rehmannia, 609g of angelica, 609g of cassia seed, 609g of loofah sponge and 140g of cassia twig.
American ginseng is a perennial herb of the genus Panax of the family Araliaceae. The root of American ginseng is cylindrical or spindle-shaped; the blade is wide oval or reverse oval, and the edge is provided with rough saw teeth; the inflorescences are umbrella-shaped, green and bell-shaped; petals are green and white, anther is oval or oblong; the berry has a flat ball shape, is bright red when cooked, and the American ginseng is firstly loaded in the 'additional herbal preparation', is bitter and cold to clear and release, is sweet and cold to supplement, enters heart, lung and kidney meridians, is a cold-supplementing product, and is good at tonifying qi and nourishing yin, clearing fire and promoting the production of body fluid, and is mainly used for treating deficiency of both qi and yin. American ginseng can also be used for treating cardiovascular diseases, enhancing immunity, inhibiting proliferation of cancer cells, invigorating qi and nourishing yin, and warming and invigorating primordial qi. Astragalus membranaceus is root of Astragalus mongholicus (Fisch.) bge or Astragalus membranaceus (Fisch.) bge of Astragalus of Leguminosae, and has effects of invigorating spleen, invigorating yang, relieving sinking, invigorating defenses, consolidating exterior, promoting urination, removing toxic substances, and promoting granulation. It is indicated for spleen qi deficiency, lung qi deficiency, spontaneous perspiration due to qi deficiency, qi and blood deficiency, and sores and ulcers, or chronic ulcer. The flos Carthami is dry stigma croci of Iridaceae. Introducing cultivars. Has effects of promoting blood circulation, removing blood stasis, cooling blood, removing toxic substance, resolving stagnation, and tranquilizing. Can be used for treating amenorrhea, puerperal stagnation, toxic heat, speckle, depression, oppression, palpitation, and mania.
The pearl has the effects of soothing the nerves, arresting convulsion, improving eyesight, removing nebula, detoxifying, promoting tissue regeneration and the like, and modern researches also show that the pearl has unique effects in improving human immunity, delaying aging, removing freckle, whitening, supplementing calcium and the like. Wild radix Puerariae contains a large amount of puerarin and flavonoids, which can not only remove cholesterol and fat in human blood, but also promote insulin secretion and prevent blood sugar rise. In addition, the wild kudzuvine root has extremely low sugar content, and can be eaten by people suffering from diabetes mellitus, and can prevent diabetes mellitus complications and keep the illness state of people stable. Dried leeches can be used as medicine, and they are salty and bitter in taste and enter liver meridian. Has effects of removing blood stasis, dredging channels, and eliminating symptoms. Is mainly used for treating amenorrhea due to blood stasis, abdominal mass, traumatic injury, heart and abdomen pain, etc. The Hirudo can extract hirudin, and has effects of reducing blood lipid, regulating blood pressure, dissolving thrombosis, resisting oxidation, scavenging free radicals, etc.
Fructus Lycii is mature fruit of Lycium barbarum of Solanaceae. The wolfberry fruit has various health care effects, and proper amount of wolfberry fruit is beneficial to health, and the wolfberry fruit tea has the effects of clearing liver and improving vision. Rehmannia root can be classified into fresh rehmannia root and dried rehmannia root; according to the records of the traditional Chinese medicine and medical books, the fresh rehmannia root is superior to the dried rehmannia root in the effects of stopping bleeding, clearing heat and promoting fluid; wherein, the following is recorded in the outline of materia medica: the fresh rehmannia root has the effects of clearing heat and promoting fluid production, cooling blood and stopping bleeding, and the dried rehmannia root has the effects of clearing heat and cooling blood, nourishing yin and promoting fluid production. Can be used for natural flower arrangement. Semen Cassiae is dry mature seed of Cassia Torae semen or Cassia tora of Leguminosae, and is named as having eyesight improving effect. Harvesting mature fruits in autumn, sun drying, threshing seeds, and removing impurities. Semen Cassiae is bitter, sweet and salty in taste, and slightly cold in nature, entering liver, kidney and large intestine meridians; relaxing bowel, reducing blood lipid, improving eyesight, and treating constipation, hyperlipidemia and hypertension. Clearing liver-fire, improving vision, promoting diuresis, relaxing bowels, reducing blood pressure and blood lipid.
The retinervus Luffae fructus has various effects, is mainly used for clearing heat and detoxicating, promoting urination and detumescence, lowering blood pressure, lowering blood sugar, etc., and polysaccharide and flavonoid in retinervus Luffae fructus has blood sugar lowering effect, and can be used for treating diabetes. Ramulus Cinnamomi belongs to Cinnamomum, lauraceae, and is a medium-sized arbor; annual branches are cylindrical, the terminal buds are in a scale wide oval shape, green leaves grow mutually, and the shape of each annual branch is oblong to be nearly in a needle shape; cutting off tender branches in spring and summer, sun drying or drying in shade, and cutting into slices or segments. Pungent, sweet and warm. It enters heart, lung and bladder meridians. Has effects of inducing sweat, relieving muscle, warming and activating meridian, supporting yang, activating qi-flowing, and calming the pulse. It is commonly used for wind-cold type common cold, abdominal cold pain, amenorrhea due to blood cold, arthralgia, phlegm retention, edema, palpitation, etc.
Referring to fig. 1, the preparation method of the traditional Chinese medicine for treating diabetic retinopathy of the application comprises the following steps:
step one, providing the following components in parts by weight: 1-840 parts of astragalus membranaceus, 1-840 parts of radix puerariae, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica sinensis, 1-609 parts of semen cassiae, 1-609 parts of luffa and 1-140 parts of cassia twig; mixing and grinding the components;
step two, heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues;
step three, heating, boiling and decocting the first medicine residues and 70% ethanol for 2 hours, and filtering to obtain second medicine liquid and second medicine residues;
step four, heating, boiling and decocting the second medicine residues and 70% ethanol for 2 hours, and filtering to obtain third medicine liquid and third medicine residues;
fifthly, mixing and filtering the first liquid medicine, the second liquid medicine and the third liquid medicine to obtain extractum;
step six, mixing and drying 1-840 parts of American ginseng, 1-119 parts of pearl and 1-140 parts of leech into powder and extractum to prepare the premixed raw material.
And seventhly, mixing and drying 1-280 parts of safflower and the premixed raw materials to prepare the traditional Chinese medicine for treating diabetic retinopathy.
Example 1
The components with the following parts by weight are provided: 400g of astragalus, chai Gegen g of medlar 420g, 300g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of luffa, and 70g of cassia twig; mixing and grinding the components; heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues; boiling the first residue and 70% ethanol for 2 hr, and filtering to obtain second liquid medicine and second residue; boiling the second residue and 70% ethanol for 2 hr, and filtering to obtain third medicinal liquid and third residue; mixing the first liquid medicine, the second liquid medicine and the third liquid medicine, and filtering to obtain extract; 400g of American ginseng, 60g of pearl and 70g of leech are crushed into powder, and the powder is mixed with the extract and dried to prepare the premix raw material. Mixing 280g of safflower with the premixed raw materials, and drying to prepare the traditional Chinese medicine for treating diabetic retinopathy.
Example two
The components with the following parts by weight are provided: 300g of astragalus, chai Gegen g of medlar, 600g of rehmannia, 400g of angelica, 400g of cassia seed, 300g of luffa, and 50g of cassia twig; mixing and grinding the components; heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues; boiling the first residue and 70% ethanol for 2 hr, and filtering to obtain second liquid medicine and second residue; boiling the second residue and 70% ethanol for 2 hr, and filtering to obtain third medicinal liquid and third residue; mixing the first liquid medicine, the second liquid medicine and the third liquid medicine, and filtering to obtain extract; 300g of American ginseng, 60g of pearl and 80g of leech are crushed into powder, and the powder is mixed with the extract and dried to prepare the premix raw material. 140g of safflower is mixed with the premixed raw materials and dried, and the traditional Chinese medicine for treating diabetic retinopathy is prepared.
Example III
The components with the following parts by weight are provided: 840g of astragalus, chai Gegen g of medlar 840g, 609g of rehmannia, 609g of angelica, 609g of cassia seed, 609g of luffa, and 140g of cassia twig; mixing and grinding the components; heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues; boiling the first residue and 70% ethanol for 2 hr, and filtering to obtain second liquid medicine and second residue; boiling the second residue and 70% ethanol for 2 hr, and filtering to obtain third medicinal liquid and third residue; mixing the first liquid medicine, the second liquid medicine and the third liquid medicine, and filtering to obtain extract; 840g of American ginseng, 119g of pearl and 140g of leech are crushed into powder, and the powder is mixed with the extract and dried to prepare the premix raw material. 100g of safflower is mixed with the premixed raw materials and dried, and the traditional Chinese medicine for treating diabetic retinopathy is prepared.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the present application. As used herein, the singular is also intended to include the plural unless the context clearly indicates otherwise, and furthermore, it is to be understood that the terms "comprises" and/or "comprising" when used in this specification are taken to specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof.
It should be noted that the terms "first," "second," and the like in the description and the claims of the present application and the above figures are used for distinguishing between similar objects and not necessarily for describing a particular sequential or chronological order. It is to be understood that the data so used may be interchanged where appropriate such that embodiments of the application described herein may be capable of being practiced otherwise than as specifically illustrated and described.
The above description is only of the preferred embodiments of the present application and is not intended to limit the present application, but various modifications and variations can be made to the present application by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (8)
1. The traditional Chinese medicine for treating diabetic retinopathy is characterized by comprising the following components in parts by weight:
1-840 parts of American ginseng, 1-840 parts of astragalus, 1-280 parts of safflower, 1-119 parts of pearl, 1-840 parts of radix puerariae, 1-140 parts of leech, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica, 1-609 parts of cassia seed, 1-609 parts of luffa and 1-140 parts of cassia twig.
2. The traditional Chinese medicine for treating diabetic retinopathy of claim 1, which is characterized by comprising the following components in parts by weight:
1-840g of American ginseng, 1-840g of astragalus, 1-280g of safflower, 1-119g of pearl, 1-840g of radix puerariae, 1-140g of leech, 1-840g of medlar, 1-609g of rehmannia, 1-609g of angelica, 1-609g of cassia seed, 1-609g of luffa and 1-140g of cassia twig.
3. The traditional Chinese medicine for treating diabetic retinopathy of claim 2, which is characterized by comprising the following components in parts by weight:
400g of American ginseng, 400g of astragalus, 140g of safflower, 60g of pearl, chai Gegen g of leech, 70g of medlar, 420g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of loofah sponge and 70g of cassia twig.
4. A traditional Chinese medicine for treating diabetic retinopathy according to claim 3, comprising the following components by weight:
840g of American ginseng, 840g of astragalus, 280g of safflower, 119g of pearl, chai Gegen g of leech, 140g of medlar 840g, 609g of rehmannia, 609g of angelica, 609g of cassia seed, 609g of loofah sponge and 140g of cassia twig.
5. The preparation method of the traditional Chinese medicine for treating diabetic retinopathy is characterized by comprising the following steps:
step one, providing the following components in parts by weight: 1-840 parts of astragalus membranaceus, 1-840 parts of radix puerariae, 1-840 parts of medlar, 1-609 parts of rehmannia, 1-609 parts of angelica sinensis, 1-609 parts of semen cassiae, 1-609 parts of luffa and 1-140 parts of cassia twig; mixing and grinding the components;
step two, heating and boiling the mixed components and 70% ethanol, decocting for 2 hours, and filtering to obtain a first liquid medicine and first residues;
step three, heating, boiling and decocting the first medicine residues and 70% ethanol for 2 hours, and filtering to obtain second medicine liquid and second medicine residues;
step four, heating, boiling and decocting the second medicine residues and 70% ethanol for 2 hours, and filtering to obtain third medicine liquid and third medicine residues;
fifthly, mixing and filtering the first liquid medicine, the second liquid medicine and the third liquid medicine to obtain extractum;
step six, mixing and drying 1-840 parts of American ginseng, 1-119 parts of pearl and 1-140 parts of leech into powder and extractum to prepare a premixed raw material;
and seventhly, mixing and drying 1-280 parts of safflower and the premixed raw materials to prepare the traditional Chinese medicine for treating diabetic retinopathy.
6. The method for preparing a traditional Chinese medicine for treating diabetic retinopathy according to claim 5, wherein in the first step, the following components by weight are provided:
1-840g of astragalus root, 1-840g of radix puerariae, 1-840g of medlar, 1-609g of rehmannia, 1-609g of angelica, 1-609g of cassia seed, 1-609g of luffa and 1-140g of cassia twig.
7. The traditional Chinese medicine for treating diabetic retinopathy of claim 6, wherein in the first step, the following components by weight are provided:
400g of astragalus, chai Gegen g of medlar 420g, 300g of rehmannia, 300g of angelica, 300g of cassia seed, 300g of luffa, and 70g of cassia twig.
8. The traditional Chinese medicine for treating diabetic retinopathy of claim 6, wherein in the first step, the following components by weight are provided:
radix astragali 840g, chai Gegen g, fructus Lycii 840g, rehmanniae radix 609g, radix Angelicae sinensis 609g, semen Cassiae 609g, retinervus Luffae fructus 609g, ramulus Cinnamomi 140g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310904798.1A CN116966234A (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310904798.1A CN116966234A (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116966234A true CN116966234A (en) | 2023-10-31 |
Family
ID=88472396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310904798.1A Pending CN116966234A (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116966234A (en) |
-
2023
- 2023-07-21 CN CN202310904798.1A patent/CN116966234A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178867B (en) | Chinese medicine preparation for replenishing qi to invigorate spleen and tonifying kidney and products thereof | |
| CN101966271B (en) | Chinese medicinal decoction for treating hypertension | |
| CN101642178A (en) | Health stomachic tea for increasing immune function and harmonizing spleen-stomach function and preparation method thereof | |
| CN104940740A (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN103735835A (en) | Traditional Chinese medicinal preparation for treating premature graying and preparation method thereof | |
| CN104958646A (en) | Chinese medicinal preparation for relaxing bowels and preparation method thereof | |
| CN104873877A (en) | Blood-sugar-lowering and body-constitution-conditioning traditional Chinese medicinal composition | |
| CN104547622A (en) | Traditional Chinese medicine preparation for treating cataract and preparation method of traditional Chinese medicine preparation | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN102366527A (en) | Traditional Chinese medicine formula for treating vitiligo | |
| CN104906507A (en) | Traditional Chinese medicine combination for lowering blood pressure and toning physical fitness | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN116966234A (en) | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof | |
| CN102327442A (en) | Method for preparing traditional Chinese medicine (TCM) lotion for treating insomnia bedsore | |
| CN105362663A (en) | Traditional Chinese medicine preparation for treating juvenile poliosis | |
| CN105055931A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN110025725A (en) | It is a kind of to treat cardiopathic drug and preparation method thereof | |
| CN104984150A (en) | Preparing technology of health maintaining porridge with blood pressure reducing effect | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN102861223A (en) | Seven-medicament diabetes treating capsule | |
| CN108421012A (en) | Hypoglycemic promotes the production of body fluid soup | |
| CN101804137B (en) | Chinese medicine film preparation used in plasma filtering device | |
| CN105106799A (en) | Prescription for treating ovarian cancer and preparation method | |
| CN105942397A (en) | Broth for treating insomnia and dysphoria and preparation method thereof | |
| CN104225311A (en) | Neurasthenia heart and spleen tonifying medicament and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |